Blockchain Registration Transaction Record
Cingulate Inc. Advances ADHD Treatment with CTx-1301, Eyes $22B Market
Cingulate Inc. advances CTx-1301 for ADHD, targeting a $22B market with a once-daily treatment. Stonegate initiates coverage, highlighting potential.

This news is significant for investors, healthcare professionals, and individuals affected by ADHD. Cingulate's CTx-1301 represents a potential breakthrough in ADHD treatment, offering a once-daily solution with rapid onset and full-day efficacy, which could significantly improve patient adherence and quality of life. The company's progress towards FDA approval and its strategic positioning in the lucrative ADHD market make it a noteworthy development in the biotech sector.
Blockchain | Details |
---|---|
Contract Address | 0xeA2912a8DA1CD48401b10cB283585874d98098F4 |
Transaction ID | 0x2a33551c6890e2bd5d73e41d4eaf99a2309a21a4bb7062e0d89432e0694878e0 |
Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
Chain | polygon-main |
NewsRamp Digital Fingerprint | boldA_Z4-ae8fdcf8cd5f1ef4ecf78de14733cb41 |